Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Up 92.9% in July

Seres Therapeutics, Inc. (NASDAQ:MCRB) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 303,423 shares, a growth of 92.9% from the June 30th total of 157,327 shares. Based on an average daily volume of 151,675 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.3% of the shares of the stock are sold short.

Seres Therapeutics Price Performance

NASDAQ:MCRB opened at $4.65 on Thursday. The firm has a market capitalization of $45.03 million, a price-to-earnings ratio of -0.90 and a beta of 0.09. The business has a 50 day simple moving average of $6.57 and a 200-day simple moving average of $8.93. Seres Therapeutics has a 1 year low of $4.59 and a 1 year high of $29.98.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.36 million. As a group, analysts expect that Seres Therapeutics will post -5.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on MCRB shares. Zacks Research upgraded shares of Seres Therapeutics to a “hold” rating in a research report on Tuesday, June 23rd. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, HC Wainwright started coverage on shares of Seres Therapeutics in a report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. lifted its stake in Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 3,918 shares during the period. 683 Capital Management LLC purchased a new position in Seres Therapeutics during the 4th quarter valued at about $778,000. ExodusPoint Capital Management LP bought a new stake in shares of Seres Therapeutics in the 4th quarter valued at about $190,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Seres Therapeutics in the 4th quarter valued at about $214,000. Finally, Barclays PLC lifted its position in shares of Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 6,024 shares during the period. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.